Docarpamine

Docarpamine is a cardiostimulant with diuretic activity launched in Japan for the treatment of circulatory insufficiency. It is an orally effective peripheral dopamine prodrug that is well absorbed from the gastrointestinal tract and converted to dopamine in vivo, which exerts renal vasodilatory and natriuretic effects by activating renal dopamine (DA₁) receptors, and a positive inotropic effect by activating cardiac β1-receptors. It has been reported to be effective in treating patients with acute heart failure, shock and acute renal failure.

Tanabe Seiyaku (Japan)

Docarpamine maybe a usefule alternative to intravenous dopamine after cardiac surgery.

ChEBI: Docarpamine is an organic molecular entity.

Tanadopa